Cargando…
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma
BACKGROUND AND AIMS: Nonalcoholic steatohepatitis (NASH) is a common inflammatory liver condition that may lead to cirrhosis and hepatocellular carcinoma (HCC). Risk factors for NASH include a saturated fat diet, altered lipid metabolism, and genetic and epigenetic factors, including microRNAs. Seru...
Autores principales: | Tucker, Robin D., Ciofoaia, Victor, Nadella, Sandeep, Gay, Martha D., Cao, Hong, Huber, Matthew, Safronenka, Anita, Shivapurkar, Narayan, Kallakury, Bhaskar, Kruger, Annie J., Kroemer, Alexander H. K., Smith, Jill P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946881/ https://www.ncbi.nlm.nih.gov/pubmed/31297627 http://dx.doi.org/10.1007/s10620-019-05722-3 |
Ejemplares similares
-
4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines
por: Gay, Martha, et al.
Publicado: (2020) -
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022) -
25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma
por: Gay, Martha Dee, et al.
Publicado: (2021) -
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022) -
Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
por: Malchiodi, Zoe X., et al.
Publicado: (2021)